BMY - Mirati Therapeutics gains as HSR waiting period for sale to Bristol-Myers expires
2023-12-19 07:46:36 ET
More on Mirati Therapeutics
- Mirati Therapeutics: Anatomy Of A Long Simmering Buyout
- Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud
- Mirati lung cancer therapy endorsed in EU
- Bristol-Myers was only firm that made real bid for Mirati Therapeutics; BMY offered $140/shr in April 2022
- Seeking Alpha’s Quant Rating on Mirati Therapeutics
For further details see:
Mirati Therapeutics gains as HSR waiting period for sale to Bristol-Myers expires